Zealand Pharma A/S
ZLDPF
$61.00
$3.506.09%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 27,971.16% | -48.04% | -61.42% | -98.49% | 223.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27,971.16% | -48.04% | -61.42% | -98.49% | 223.87% |
| Cost of Revenue | -95.44% | -91.47% | -96.57% | -229.39% | 280.13% |
| Gross Profit | 38,779.12% | -29.02% | -25.38% | -96.17% | 55.90% |
| SG&A Expenses | 44.11% | 32.13% | 139.28% | 90.45% | 44.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -5,922.08% | 308.43% | -- |
| Total Operating Expenses | 161.93% | 48.44% | 50.96% | 42.67% | 44.84% |
| Operating Income | 3,384.00% | -54.13% | -61.73% | -878.64% | -35.31% |
| Income Before Tax | 3,007.76% | -41.83% | -8.80% | -470.99% | 9.55% |
| Income Tax Expenses | 43,140.49% | 1.42% | 0.36% | -5.36% | 16.05% |
| Earnings from Continuing Operations | 2,827.34% | -42.09% | -8.82% | -462.53% | 9.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2,827.34% | -42.09% | -8.82% | -462.53% | 9.51% |
| EBIT | 3,384.00% | -54.13% | -61.73% | -878.64% | -35.31% |
| EBITDA | 3,471.63% | -55.91% | -61.74% | -799.94% | -41.11% |
| EPS Basic | 2,517.38% | -24.03% | 10.19% | -399.46% | 16.15% |
| Normalized Basic EPS | 2,596.02% | -27.84% | 4.42% | -435.63% | -49.71% |
| EPS Diluted | 2,484.19% | -24.03% | 10.19% | -409.30% | 16.15% |
| Normalized Diluted EPS | 2,561.76% | -27.84% | 4.42% | -446.35% | -49.71% |
| Average Basic Shares Outstanding | 12.83% | 14.55% | 21.18% | 21.03% | 7.91% |
| Average Diluted Shares Outstanding | 14.40% | 14.55% | 21.18% | 17.22% | 7.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |